Mr. Chair, absolutely the point is well taken that communications need to be very carefully done when it comes to drug shortages. You don't want to precipitate any panic buying. What we've seen specifically with Tylenol and ibuprofen is that there was some tightness in supply back in the spring. There was an increase in supply as manufacturers stepped up to ramp up production. There were intermittent stock outages in different places, but really it was in August when there was more attention to the issue. That's when we saw this huge, drastic increase in purchasing. That's when it tripled and quadrupled, in August.
Again, it was variable across the country, but that's when we really had from the manufacturers the notification that they were unlikely to meet supply, and we then went to working with looking at alternatives to supply. That's when a lot of the communication started as well. We worked with the Canadian Paediatric Society to put out advice to patients. We worked with other stakeholders as well. Again, we had seen in August that some attention to this and some of the communications around it encouraged people to go out and potentially stock up and buy more than they needed. That's really when we started to see some of that shift in not being able to meet the demand nationally.